VOR vs. UPB, PGEN, CRON, VALN, NBTX, SYRE, DNA, RLAY, SANA, and BGM
Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Upstream Bio (UPB), Precigen (PGEN), Cronos Group (CRON), Valneva (VALN), Nanobiotix (NBTX), Spyre Therapeutics (SYRE), Ginkgo Bioworks (DNA), Relay Therapeutics (RLAY), Sana Biotechnology (SANA), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry.
Vor Biopharma vs. Its Competitors
Upstream Bio (NASDAQ:UPB) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.
Vor Biopharma has a net margin of 0.00% compared to Upstream Bio's net margin of -3,836.58%. Vor Biopharma's return on equity of 0.00% beat Upstream Bio's return on equity.
Upstream Bio currently has a consensus price target of $53.33, suggesting a potential upside of 165.60%. Vor Biopharma has a consensus price target of $113.83, suggesting a potential upside of 252.53%. Given Vor Biopharma's higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Upstream Bio.
In the previous week, Vor Biopharma had 11 more articles in the media than Upstream Bio. MarketBeat recorded 15 mentions for Vor Biopharma and 4 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.50 beat Vor Biopharma's score of 0.44 indicating that Upstream Bio is being referred to more favorably in the media.
97.3% of Vor Biopharma shares are held by institutional investors. 13.6% of Upstream Bio shares are held by company insiders. Comparatively, 0.5% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Vor Biopharma has lower revenue, but higher earnings than Upstream Bio.
Summary
Vor Biopharma beats Upstream Bio on 7 of the 11 factors compared between the two stocks.
Get Vor Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vor Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:VOR) was last updated on 10/14/2025 by MarketBeat.com Staff
